Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 5/20 | 0.69 |
| ▸ | LMNA | P02545 | 4/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | RECQL | P46063 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | ESR1 | P03372 | 4/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.55 |
| ▸ | PGR | P06401 | 1/20 | 0.55 |
| ▸ | CNR1 | P21554 | 1/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.55 |
| ▸ | STS | P08842 | 5/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30844889 | 1.00 | HSD17B1 (0.69) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 | |
| SCHEMBL7933639 | 1.00 | HSD17B1 (0.69) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 | |
| SCHEMBL309293 | 1.00 | HSD17B1 (0.69) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 | |
| Sulfuric Acid SCHEMBL2837738 | 0.96 | LMNA (0.64) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 | |
| SCHEMBL15979565 | 0.88 | HSD17B1 (0.71) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 | |
| SCHEMBL11231177 | 0.88 | HSD17B1 (0.71) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 | |
| SCHEMBL11865928 | 0.87 | ESR1 (0.74) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 | |
| SCHEMBL9558249 | 0.87 | LMNA (0.69) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 | |
| SCHEMBL14652461 | 0.87 | LMNA (0.69) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 | |
| SCHEMBL12164089 | 0.87 | HSD17B1 (0.69) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 392 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6365186-B1 | ADMINISTERING TO PATIENT UNSUBSTITUTED POLYDIALLYLAMINE POLYMER AND CHOLESTEROL-LOWERING AGENT IN THERAPEUTICALLY EFFECTIVE AMOUNT | GELTEX PHARMACEUTICALS, INC. | 2002-04-02 | — | — | US | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000069445-A1 | COMBINATION THERAPY FOR TREATING HYPERCHOLESTEROLEMIA | GELTEX PHARMACEUTICALS, INC. (US) | 2000-11-23 | — | — | WO | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-12605384-B2 | Uses | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| EP-3746081-B1 | PDE1 INHIBITORS FOR USE TO TREAT CARDIAC FAILURE AND CARDIOTOXICITY | INTRA CELLULAR THERAPIES INC (US) | 2026-04-01 | — | — | EP | disclosed |
| US-20260049314-A1 | ANTISENSE OLIGONUCLEOTIDE-BASED ANTI-FIBROTIC THERAPEUTICS | UNIVERSITY OF ROCHESTER (US) | 2026-02-19 | — | — | US | disclosed |
| EP-4581143-A1 | ANTISENSE OLIGONUCLEOTIDE-BASED ANTI-FIBROTIC THERAPEUTICS | University of Rochester (US) | 2025-07-09 | — | — | EP | disclosed |
| US-20250066790-A1 | ANTISENSE OLIGONUCLEOTIDES FOR MODIFYING PROTEIN EXPRESSION | UNIVERSITY OF ROCHESTER | 2025-02-27 | — | — | US | disclosed |
| US-20250019702-A1 | GATA4-TARGETED THERAPEUTICS FOR TREATMENT OF CARDIAC HYPERTROPHY | UNIVERSITY OF ROCHESTER | 2025-01-16 | — | — | US | disclosed |
| US-20250018009-A1 | SERUM RESPONSE FACTOR REGENERATES SENESCENT CELLS | UNIVERSITY OF HOUSTON SYSTEM (US) | 2025-01-16 | — | — | US | disclosed |
| US-20020155432-A1 | Genetically engineered herpes virus for the treatment of cardiovascular disease | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-10-24 | — | — | US | disclosed |
| WO-2002045431-A2 | GENETICALLY ENGINEERED HERPES VIRUS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE | THE UNIVERSITY OF CHICAGO (US) | 2002-06-06 | — | — | WO | disclosed |
| US-6365186-B1 | ADMINISTERING TO PATIENT UNSUBSTITUTED POLYDIALLYLAMINE POLYMER AND CHOLESTEROL-LOWERING AGENT IN THERAPEUTICALLY EFFECTIVE AMOUNT | GELTEX PHARMACEUTICALS, INC. | 2002-04-02 | — | — | US | disclosed |
| US-6239122-B1 | Method of treatment of nausea, vomiting, and other disorders using estrogens | STEELE JOY ANN (CA) | 2001-05-29 | — | — | US | disclosed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | disclosed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | disclosed |
| WO-2000069445-A1 | COMBINATION THERAPY FOR TREATING HYPERCHOLESTEROLEMIA | GELTEX PHARMACEUTICALS, INC. (US) | 2000-11-23 | — | — | WO | disclosed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049314-A1 | ANTISENSE OLIGONUCLEOTIDE-BASED ANTI-FIBROTIC THERAPEUTICS | UPF1, HNRNPF, RNMT | HSD17B1 4867/4885LMNA 781/4885MAPT 2836/4885 |
| US-20250019702-A1 | GATA4-TARGETED THERAPEUTICS FOR TREATMENT OF CARDIAC HYPERTROPHY | UPF1, TNNI3, TNNT2 | HSD17B1 4243/4885LMNA 304/4885MAPT 4037/4885 |
| US-12605384-B2 | Uses | PDE2A, NPR1, PDE7A | HSD17B1 2659/4885LMNA 1054/4885MAPT 4884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.